Major Depressive Disorder (MDD) is the leading cause of disability world wide. It is thought that MDD is caused by a combination of biological, genetic, psychological, and environmental factors. While there are effective treatments for MDD, fewer than half of those affected receive treatment. One of the many barriers to receiving treatment is inaccurate diagnosis or under-diagnosis.
Currently, accurate diagnosis for MDD is challenging and time consuming as it entails extensive clinical assessment with subjective criteria that may co-exist with other mood disorders. Likewise, there is no objective diagnostic test available for monitoring the efficacy of antidepressive medications.
A blood test to accurately diagnose and monitor treatment efficacy for MDD could provide additional valuable information to physicians treating mood disorders.
Paradise Genomics is discovering biomarkers that can distinguish mood disorders including MDD, Bipolar Disorder, Attention Deficit Hyperactivity Disorder, and Post Traumatic Stress Disorder.